We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Acacia Pharma Group Plc | LSE:0PNT | London | Ordinary Share | GB00BYWF9Y76 | ACACIA PHARM ORD SHS |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 0.00 | - |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
TIDMACPH
This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.
Cambridge, UK and Indianapolis, US -- 29 April 2022, 23:00 CEST: Acacia Pharma Group plc ("Acacia Pharma", the "Group" or the "Company") (EURONEXT: ACPH), a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures or cancer chemotherapy, announces the publication of its Annual Report and Financial Statements for the Year ended 31 December 2021.
The Annual Report is attached below and also available on https://www.globenewswire.com/Tracker?data=unUxIJxP3Ho3jmNAHo0ioWOzcEgFHq1Z6okOQWElMbQ6fUiLVULHZwDDCORHEOfpXkl-Q3Y_Ed-4BbmTzjNRprk0FgJppkVo_ylWKSndiPM= www.acaciapharma.com in the Investors/Financial Reports and Presentations section.
Contacts
Hot Features
Premium
Acacia Pharma Group plc International Media
Mike Bolinder, CEO Frazer Hall, Mark Swallow, David
+44 1223 919760 / +1 317 505 1280 Dible
mailto:IR@acaciapharma.com IR@acaciapharma.com MEDiSTRAVA Consulting
+44 20 3928 6900
mailto:acaciapharma@medistrava.com
acaciapharma@medistrava.com
----------------------------------------------- ------------------------------------
US Investors Media in Belgium and the Netherlands
LifeSci Advisors Chris Van Raemdonck
Irina Koffler +32 499 58 55 31
+1 917-734-7387 mailto:chrisvanraemdonck@telenet.be
mailto:ikoffler@lifesciadvisors.com chrisvanraemdonck@telenet.be
ikoffler@lifesciadvisors.com
----------------------------------------------- ------------------------------------
Attachment
-- Acacia Pharma Annual Report 2021
https://ml-eu.globenewswire.com/Resource/Download/5cb8d7f5-83d3-49a4-8f52-02a8da4cb3a7
(END) Dow Jones Newswires
April 29, 2022 17:02 ET (21:02 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Acacia Pharma Chart |
1 Month Acacia Pharma Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
